Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management

COVID-19: A systematic review and update on prevention, diagnosis, and treatment

Since the rapid onset of the COVID-19 or SARS-CoV-2 pandemic in the world in 2019, extensive studies have been conducted to unveil the behavior and emission pattern of the virus in order to determine the best ways to diagnosis of virus and thereof formulate effective drugs or vaccines to combat the disease. The emergence of novel diagnostic and therapeutic techniques considering the multiplicity of reports from one side and contradictions in assessments from the other side necessitates instantaneous updates on the progress of clinical investigations. There is also growing public anxiety from time to time mutation of COVID-19, as reflected in considerable mortality and transmission, respectively, from delta and Omicron variants. We comprehensively review and summarize different aspects of prevention, diagnosis, and treatment of COVID-19. First, biological characteristics of COVID-19 were explained from diagnosis standpoint. Thereafter, the preclinical animal models of COVID-19 were discussed to frame the symptoms and clinical effects of COVID-19 from patient to patient with treatment strategies and in-silico/computational biology. Finally, the opportunities and challenges of nanoscience/nanotechnology in identification, diagnosis, and treatment of COVID-19 were discussed. This review covers almost all SARS-CoV-2-related topics extensively to deepen the understanding of the latest achievements (last updated on January 11, 2022).

Evaluación de los planes de contingencia en la atención a pacientes en unidades de cuidados intensivos en la pandemia COVID-19

Introducción

La expansión de las áreas de cuidados de intensivos ha sido una de las medidas más significativas en esa obligada adaptación a la evolución de las distintas fases de la pandemia por la COVID-19. El objetivo es evaluar el despliegue de los planes de contingencia en la atención a pacientes ingresados en Unidades de Cuidados Intensivos (UCI) durante el periodo del 19 de marzo al 20 de abril de 2020, en un hospital público, referencia para 300.000 habitantes, perteneciente al Servicio Galego de Saúde.

Materiales y métodos

Investigación cualitativa a partir de grupos focales, con muestreo sistemático. A partir de la adaptación al entorno sanitario de las 10 medidas recomendadas por Deloitte para afrontar una pandemia, se realizó una evaluación por la Unidad de Calidad del Área Sanitaria. Como indicadores de resultados, se evaluaron el número de pacientes con COVID-19, porcentaje de pacientes con ingreso hospitalario, % de pacientes con ingreso en UCI, así como el número de fallecidos por COVID-19, en siete áreas sanitarias en el periodo del 19 marzo al 20 de abril de 2020.

Resultados

La evaluación cualitativa identificó dos áreas de mejora (comunicación y evaluación de riesgos) de las 10 medidas recomendadas (80%).

El área sanitaria presenta la menor tasa relativa (2,6%) y absoluta (16) de pacientes fallecidos, así como la menor tasa relativa (7,9%) y absoluta (24) de pacientes ingresados en servicios de intensivos por COVID-19. La tasa de infección en profesionales ha sido de 4,4%.

Conclusiones

La simplicidad e identificación de áreas de mejora sumado al escaso consumo de recursos son fortalezas de esta propuesta. Esta autoevaluación puede ser útil para detectar áreas de mejora.

Coronavirus Disease (COVID-19) Caused by (SARS-CoV-2) Infections: A Real Challenge for Human Gut Microbiota

The current COVID-19 pandemic is a great challenge for worldwide researchers in the human microbiota area because the mechanisms and long-term effects of the infection at the GI level are not yet deeply understood. In the current review, scientific literature including original research articles, clinical studies, epidemiological reports, and review-type articles concerning human intestinal infection with SARS-CoV-2 and the possible consequences on the microbiota were reviewed. Moreover, the following aspects pertaining to COVID-19 have also been discussed: transmission, resistance in the human body, the impact of nutritional status in relation to the intestinal microbiota, and the impact of comorbid metabolic disorders such as inflammatory bowel disease (IBS), obesity, and type two diabetes (T2D). The articles investigated show that health, age, and nutritional status are associated with specific communities of bacterial species in the gut, which could influence the clinical course of COVID-19 infection. Fecal microbiota alterations were associated with fecal concentrations of SARS-CoV-2 and COVID-19 severity. Patients suffering from metabolic and gastrointestinal (GI) disorders are thought to be at a moderate-to-high risk of infection with SARS-CoV-2, indicating the direct implication of gut dysbiosis in COVID-19 severity. However, additional efforts are required to identify the initial GI symptoms of COVID-19 for possible early intervention.

Increased Complement Receptor-3 levels in monocytes and granulocytes distinguish COVID-19 patients with pneumonia from those with mild symptoms

•

COVID-19 lung failure specifically correlates with a marker of peripheral blood cell immune activation.

•

Our findings suggest its use as a prognostic test for hypoxia.

•

Novel insight into COVID-19 related lung damage prompts possibilities for new treatment strategies.

Background

The reasons why some patients with COVID-19 develop pneumonia and others do not are unclear. To better understand this, we used multiparameter flow cytometry to profile circulating leukocytes from non-immunocompromised adult patients with PCR-proven COVID-19 and specifically compared those with mild symptoms with those who had developed pneumonia.

Methods

Using clinically validated antibody panels we studied leukocytes from 29 patients with PCR-proven COVID-19. Ten were hypoxic requiring ventilatory support, eleven were febrile but otherwise well, and eight were convalescing having previously required ventilatory support. Additionally, we analysed patients who did not have COVID-19 but received ventilatory support for other reasons. We examined routine Full Blood Count (FBC) specimens that were surplus to routine diagnostic requirements; normal ranges were established in a historic group of healthy volunteers.

Findings

We observed striking and unexpected differences in cells of the innate immune system. Levels of CD11b and CD18, which together comprise Complement Receptor 3 (CR3), were increased in granulocytes and monocytes from hypoxic COVID-19 patients, but not in those with COVID-19 who remained well, or in those without COVID-19 but ventilated for other reasons. Granulocyte and monocyte numbers were unchanged, however Natural Killer (NK) cell numbers were two-fold higher than normal in COVID-19 patients who remained well.

Interpretation

CR3 is central to leukocyte activation and subsequent cytokine release in response to infection. It is also a fibrinogen receptor, and its over-expression in granulocytes and monocytes of patients with respiratory failure tables it as a candidate effector of both the thrombotic and inflammatory features of COVID-19 pneumonia, and both a biomarker of impending respiratory failure and potential therapeutic target. NK cells are innate immune cells that retain immunological memory. Rapid expansion of memory NK cells targeting common antigens shared with other Coronaviruses may explain why most patients with COVID-19 do not develop respiratory complications. Understanding the innate immune response to SARS-CoV-may uncover why most infected individuals experience mild symptoms, and inform a preventive approach to COVID-19 pneumonia in the future.

Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management

The COVID-19 pandemic poses great challenges for healthcare workers around the world, including perioperative specialists. Previously, we provided a first overview of available literature on SARS-CoV-2 and COVID-19, relevant for anaesthetists and intensivists. In the current review, we provide an update of this topic, after a literature search current through May 2020. We discuss the evidence on perioperative risk for COVID-19 patients presenting for surgery, the risk of transmission of SARS-CoV-2 in the operating room, and the current literature on laboratory diagnostics. Furthermore, cardiovascular and nervous system involvement in COVID-19 are discussed, as well as considerations in diabetic patients. Lastly, the latest evidence on pharmacological treatment is summarised.